Literature DB >> 15551121

Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease.

M K Lai1, S W Tsang, J T Alder, J Keene, T Hope, M M Esiri, P T Francis, C P Chen.   

Abstract

RATIONALE: Previous studies have demonstrated reductions of serotonin 5-HT 2A receptors in the neocortex of Alzheimer's disease (AD) patients. However, it is unclear whether such losses play a role in the cognitive decline of AD.
OBJECTIVES: To correlate neocortical 5-HT 2A receptor alterations with cognitive decline in AD.
METHODS: Postmortem frontal and temporal cortical 5-HT 2A receptors were measured by [3H]ketanserin binding in aged controls as well as in a cohort of AD patients who had been longitudinally assessed for cognitive decline and behavioral symptoms.
RESULTS: 5-HT 2A receptor densities in both regions were reduced in severely demented AD patients compared to age-matched controls. In the temporal cortex, this reduction also correlated with the rate of decline of Mini-Mental State Examination (MMSE) scores. The association between 5-HT 2A receptor loss and cognitive decline was independent of the effects of choline acetyltransferase (ChAT) activity and presence of behavioral symptoms.
CONCLUSIONS: Our data suggest that loss of neocortical 5-HT 2A receptors may predict for faster cognitive decline in AD, and point to serotomimetics as potentially useful adjuvants to cholinergic replacement therapies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15551121     DOI: 10.1007/s00213-004-2077-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  26 in total

1.  Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes.

Authors:  C P Chen; S L Eastwood; T Hope; B McDonald; P T Francis; M M Esiri
Journal:  Neuropathol Appl Neurobiol       Date:  2000-08       Impact factor: 8.090

2.  Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms.

Authors:  A W Procter; P T Francis; G C Stratmann; D M Bowen
Journal:  Neurochem Res       Date:  1992-09       Impact factor: 3.996

Review 3.  Role of serotonin in memory impairment.

Authors:  M C Buhot; S Martin; L Segu
Journal:  Ann Med       Date:  2000-04       Impact factor: 4.709

4.  Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC.

Authors:  G A McPherson
Journal:  J Pharmacol Methods       Date:  1985-11

5.  Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication.

Authors:  C P Chen; J T Alder; D M Bowen; M M Esiri; B McDonald; T Hope; K A Jobst; P T Francis
Journal:  J Neurochem       Date:  1996-04       Impact factor: 5.372

6.  Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone.

Authors:  J Blin; J C Baron; B Dubois; C Crouzel; M Fiorelli; D Attar-Lévy; B Pillon; D Fournier; M Vidailhet; Y Agid
Journal:  Brain       Date:  1993-06       Impact factor: 13.501

7.  Hallucinations, delusions, and cognitive decline in Alzheimer's disease.

Authors:  R S Wilson; D W Gilley; D A Bennett; L A Beckett; D A Evans
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-08       Impact factor: 10.154

8.  Behaviour changes in dementia. 2: Are there behavioural syndromes?

Authors:  T Hope; J Keene; C Fairburn; R McShane; R Jacoby
Journal:  Int J Geriatr Psychiatry       Date:  1997-11       Impact factor: 3.485

9.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain.

Authors:  P J Whitehouse; D L Price; R G Struble; A W Clark; J T Coyle; M R Delon
Journal:  Science       Date:  1982-03-05       Impact factor: 47.728

10.  Postmortem serotoninergic correlates of cognitive decline in Alzheimer's disease.

Authors:  Mitchell K P Lai; Shirley W Y Tsang; Paul T Francis; Janet Keene; Tony Hope; Margaret M Esiri; Ian Spence; Christopher P L-H Chen
Journal:  Neuroreport       Date:  2002-07-02       Impact factor: 1.837

View more
  32 in total

Review 1.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

2.  Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease.

Authors:  Mitchell K P Lai; Shirley W Tsang; Margaret M Esiri; Paul T Francis; Peter T-H Wong; Christopher P Chen
Journal:  Psychopharmacology (Berl)       Date:  2010-07-13       Impact factor: 4.530

Review 3.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

Review 4.  Serotonergic system, cognition, and BPSD in Alzheimer's disease.

Authors:  Saikat Chakraborty; Jack C Lennon; Sridhar A Malkaram; Yan Zeng; Daniel W Fisher; Hongxin Dong
Journal:  Neurosci Lett       Date:  2019-04-01       Impact factor: 3.046

Review 5.  Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.

Authors:  Kentaro Hirao; Gregory M Pontone; Gwenn S Smith
Journal:  Neurosci Biobehav Rev       Date:  2014-11-20       Impact factor: 8.989

6.  Single-Base Resolution Mapping of 5-Hydroxymethylcytosine Modifications in Hippocampus of Alzheimer's Disease Subjects.

Authors:  Elizabeth M Ellison; Melissa A Bradley-Whitman; Mark A Lovell
Journal:  J Mol Neurosci       Date:  2017-09-02       Impact factor: 3.444

7.  Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy.

Authors:  D M Bowen; A W Procter; D M A Mann; J S Snowden; M M Esiri; D Neary; P T Francis
Journal:  Psychopharmacology (Berl)       Date:  2007-11-18       Impact factor: 4.530

8.  Characterization of histamine H3 receptors in Alzheimer's Disease brain and amyloid over-expressing TASTPM mice.

Authors:  A D Medhurst; J C Roberts; J Lee; C P L-H Chen; S H Brown; S Roman; M K P Lai
Journal:  Br J Pharmacol       Date:  2009-02-16       Impact factor: 8.739

9.  Long-term neuropsychological effects of ecstasy in middle-aged ecstasy/polydrug users.

Authors:  Thelma Schilt; Maarten W J Koeter; Johan P Smal; Mathilde N Gouwetor; Wim van den Brink; Ben Schmand
Journal:  Psychopharmacology (Berl)       Date:  2009-10-13       Impact factor: 4.530

10.  Selective loss of P2Y2 nucleotide receptor immunoreactivity is associated with Alzheimer's disease neuropathology.

Authors:  Mitchell K P Lai; Michelle G K Tan; Sara Kirvell; Carl Hobbs; Jasinda Lee; Margaret M Esiri; Christopher P Chen; Paul T Francis
Journal:  J Neural Transm (Vienna)       Date:  2008-05-28       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.